Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
Gerasimos S FilippatosStefan D AnkerPhyllis AugustAndrew J S CoatsJames L JanuzziBoris MankovskyEllen BurgessLuis M RuilopeBertram PittPantelis A SarafidisJohn R TeerlinkChris J KapeliosMartin GebelMeike BrinkerAmer JosephAndrea LageGeorge BakrisRajiv Agarwalnull nullPublished in: European heart journal. Cardiovascular pharmacotherapy (2023)
In FIDELITY, finerenone significantly reduced the risk of all-cause and cardiovascular mortality vs. placebo in patients with T2D across a broad spectrum of CKD stages while on treatment, as well as sudden cardiac death in the intention-to-treat population.